ArticleCureus2026
High Immunohistochemical Expression of Runt-Related Transcription Factor 2 (RUNX2) Is Associated With High Tumor Grade, Muscle Invasion, Lymph Node Metastasis, and Advanced Stage in Urinary Bladder Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunohistochemical Evaluation of RUNX2, Osteocalcin, and Vimentin in Feline Primary Pulmonary Carcinomas.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Urinary bladder cancer is a common malignancy worldwide and remains a significant contributor to cancer-related morbidity and mortality. The recent shift towards personalized oncology has led to the investigation and adoption of various biomarkers as therapeutic targets. However, validated biomarkers predicting tumor behavior and progression in bladder cancer remain limited. The Runt-related transcription factor (RUNX) proteins are transcription factors playing key roles in signaling pathways associated with cancer development. There are limited studies in the literature addressing the role of RUNX2 in urinary bladder cancers. Therefore, we have attempted to analyze the immunohistochemical expression of RUNX2 in urinary bladder cancer in this study and to evaluate the significance of its immunoexpression in relation to clinicopathological parameters such as age and gender of patient, tumor size and site, tumor grade, histological subtype, muscle invasion, lymph node metastasis, and pTNM stage. Materials and methods This observational study was carried out in the Pathology department of our institute. Sixty histopathologically confirmed consecutive cases of urinary bladder carcinoma over a period from 1st January 2022 to 31st March 2025 were included. Immunohistochemistry was performed on these cases using archival paraffin blocks and the RUNX2 antibody. The final immunohistochemical results were analyzed in relation to clinicopathological variables. Result The data were analyzed using SPSS (version 23.0, IBM Corp., Armonk, New York, USA). To assess statistical significance (p-value) and correlations, the chi-square test and Fisher's exact test were used. For establishing statistical significance, a p-value of less than 0.05 was considered. High immunohistochemical expression of RUNX2 exhibited a significant association (p < 0.05) with high tumor grade, muscle invasion, lymph node metastasis, and advanced stage (pTNM) of the tumor. Conclusions This study documents that there exists a statistically significant association between immunoexpression of RUNX2 and grade of tumor, muscle invasion, advanced stage, and lymph node metastasis in urinary bladder cancers, which can guide further management and treatment and can be utilized in the near future for the development of targeted therapy for urinary bladder cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.